{
  "id": "7c6fe65377c4d101",
  "title": "Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U . S ., China and Japan",
  "description": "20260113T051500Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2026-01/67416591-eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan-011.htm",
  "published_at": "20260113T051500Z",
  "fetched_at": "2026-01-14T00:24:05.619157+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai",
    "china"
  ],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2026-01/67416591-eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan-011.htm",
    "url_mobile": "",
    "title": "Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U . S ., China and Japan",
    "seendate": "20260113T051500Z",
    "socialimage": "https://www.finanznachrichten.de/chart-eisai-co-ltd-aktie-intraklein-tradegate.png",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}